The stock of Wave Life Sciences Ltd (NASDAQ:WVE) reached all time high today, Nov, 24 and still has $41.62 target or 7.00% above today’s $38.90 share price. This indicates more upside for the $903.57 million company. This technical setup was reported by Barchart.com. If the $41.62 PT is reached, the company will be worth $63.25 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. The stock increased 3.60% or $1.35 on November 23, hitting $38.9. About 34,349 shares traded hands. Wave Life Sciences Ltd (NASDAQ:WVE) has risen 187.72% since April 22, 2016 and is uptrending. It has outperformed by 182.31% the S&P500.
Analysts await Wave Life Sciences Ltd (NASDAQ:WVE) to report earnings on March, 29. They expect $-0.69 EPS, down 46.81% or $0.22 from last year’s $-0.47 per share. After $-0.75 actual EPS reported by Wave Life Sciences Ltd for the previous quarter, Wall Street now forecasts -8.00% EPS growth.
Wave Life Sciences Ltd (NASDAQ:WVE) Ratings Coverage
Out of 5 analysts covering WAVE Life Sciences (NASDAQ:WVE), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. WAVE Life Sciences has been the topic of 5 analyst reports since December 7, 2015 according to StockzIntelligence Inc. The rating was initiated by Leerink Swann on Monday, December 7 with “Outperform”. The rating was initiated by Suntrust Robinson with “Buy” on Monday, December 7. The company was initiated on Monday, December 7 by Jefferies. The firm earned “Buy” rating on Monday, December 7 by SunTrust. The stock of Wave Life Sciences Ltd (NASDAQ:WVE) earned “Mkt Outperform” rating by JMP Securities on Monday, December 7.
According to Zacks Investment Research, “WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington’s disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington’s disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.”
More notable recent Wave Life Sciences Ltd (NASDAQ:WVE) news were published by: Marketwatch.com which released: “WAVE Life Sciences Ltd.” on October 14, 2015, also Businesswire.com with their article: “WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically …” published on May 05, 2016, Businesswire.com published: “WAVE Life Sciences to Advance Next-Generation Nucleic Acid Therapies to …” on May 09, 2016. More interesting news about Wave Life Sciences Ltd (NASDAQ:WVE) were released by: Businesswire.com and their article: “WAVE Life Sciences to Present at the Jefferies 2016 London Healthcare Conference” published on November 07, 2016 as well as Businesswire.com‘s news article titled: “WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018” with publication date: January 29, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.